Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.

In this episode, we discuss:

• Lars’ experience overcoming Treatment-Resistant Depression with psilocybin
• The nuances of clinical trials and psilocybin dosing protocols
• Compass Pathways’ Intellectual Property strategy
• What additional indications and therapies Compass Pathways is interested in

Links to topics discussed in this episode:
Compass Pathways, Lars Wilde
COMP360
SSRI, SNRI
Christian Angermayer, Robin Carhart-Harris, Michael Pollan
Vivaneo
Quercis Pharma
TRD (Therapy-Resistant Depression)
Compass Phase 2B Trial
Jazz Pharmaceuticals
Compass Pathways 2 US patents
Oregon Psilocybin Therapy Measure 109

Read the transcript here.
Watch episode 10 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Hosts: Matias Serebrinsky and Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: River Meditation by Jason Shaw and Thea by Muted Circus